ReviewBritish journal of clinical pharmacology2015
CGRP as a neuropeptide in migraine: lessons from mice.
Review in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 48 citations in OpenAlex.
- Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond.The journal of headache and pain · 2026Review
- Hyperventilation-Induced High-Amplitude Rhythmic Slowing and Its Impact on Migraine Frequency in Children: A Retrospective Observational Cohort Study.Iranian journal of child neurology · 2026Article
- Pain in the body, harm to the heart: advances in research on the impact of chronic pain on cardiovascular diseases.Frontiers in cardiovascular medicine · 2025Review
- Animal Models of Chronic Migraine: From the Bench to Therapy.Current pain and headache reports · 2024Review
- An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies.Journal of visualized experiments : JoVE · 2024Article
- Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs.Journal of virology · 2024Article
- Article
- High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2024Review
- From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.Cells · 2023Review
- The Epigenetics of Migraine.International journal of molecular sciences · 2023Review
- Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists.International journal of molecular sciences · 2022Article
- Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation.Frontiers in pharmacology · 2022Article
- Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.Neurology and therapy · 2021Review
- Immune Actions on the Peripheral Nervous System in Pain.International journal of molecular sciences · 2021Review
- A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine.The Journal of pharmacy and pharmacology · 2020Article
- Review
- Spinal Mobilization Prevents NGF-Induced Trunk Mechanical Hyperalgesia and Attenuates Expression of CGRP.Frontiers in neuroscience · 2020Article
- Current understanding of cortical structure and function in migraine.Cephalalgia : an international journal of headache · 2019Review
- Pain and immunity: implications for host defence.Nature reviews. Immunology · 2019Review
- The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.The journal of headache and pain · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Migraine is a neurological disorder that is far more than just a bad headache. A hallmark of migraine is altered sensory perception. A likely contributor to this altered perception is the neuropeptide calcitonin gene-related peptide (CGRP). Over the past decade, CGRP has become firmly established as a key player in migraine. Although the mechanisms and sites of action by which CGRP might trigger migraine remain speculative, recent advances with mouse models provide some hints. This brief review focuses on how CGRP might act as both a central and peripheral neuromodulator to contribute to the migraine-like symptom of light aversive behaviour in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.